AMI Asset Management Corp Takes $1.65 Million Position in Inari Medical, Inc. (NASDAQ:NARI)

AMI Asset Management Corp bought a new position in Inari Medical, Inc. (NASDAQ:NARI) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 32,343 shares of the company’s stock, valued at approximately $1,651,000. AMI Asset Management Corp owned 0.06% of Inari Medical as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Aigen Investment Management LP purchased a new position in shares of Inari Medical during the third quarter valued at approximately $428,000. Vestal Point Capital LP raised its stake in Inari Medical by 342.9% in the third quarter. Vestal Point Capital LP now owns 1,550,000 shares of the company’s stock worth $63,922,000 after buying an additional 1,200,000 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in Inari Medical in the third quarter worth about $1,397,000. Lighthouse Investment Partners LLC bought a new stake in Inari Medical during the 2nd quarter valued at approximately $2,145,000. Finally, Verition Fund Management LLC purchased a new position in shares of Inari Medical during the 3rd quarter worth approximately $1,235,000. 90.98% of the stock is currently owned by institutional investors.

Inari Medical Stock Up 0.2 %

Shares of Inari Medical stock opened at $79.55 on Tuesday. The stock’s fifty day moving average is $58.08 and its 200 day moving average is $50.90. Inari Medical, Inc. has a one year low of $36.73 and a one year high of $79.69.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Oppenheimer initiated coverage on Inari Medical in a research note on Tuesday, December 17th. They issued an “outperform” rating and a $75.00 target price for the company. Wells Fargo & Company reissued an “equal weight” rating and set a $80.00 price objective (up previously from $65.00) on shares of Inari Medical in a research note on Tuesday, January 7th. Canaccord Genuity Group reissued a “hold” rating and issued a $80.00 target price (up from $74.00) on shares of Inari Medical in a report on Tuesday, January 7th. BTIG Research reiterated a “neutral” rating on shares of Inari Medical in a report on Wednesday, January 8th. Finally, William Blair reaffirmed a “market perform” rating on shares of Inari Medical in a research report on Tuesday, January 7th. Twelve analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $68.00.

Insider Transactions at Inari Medical

In other Inari Medical news, CEO Andrew Hykes sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 29th. The stock was sold at an average price of $50.00, for a total value of $150,000.00. Following the completion of the transaction, the chief executive officer now directly owns 445,310 shares in the company, valued at $22,265,500. This represents a 0.67 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director William Hoffman sold 40,000 shares of Inari Medical stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $50.05, for a total transaction of $2,002,000.00. Following the completion of the sale, the director now owns 561,233 shares in the company, valued at approximately $28,089,711.65. This represents a 6.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 366,000 shares of company stock valued at $20,821,070 over the last quarter. 10.60% of the stock is currently owned by company insiders.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.